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Background: Hyperphosphatemia is common in dialysis patients and is influenced significantly by dietary
protein intake. In this study, we investigated phosphorous control and the metabolic balance of phosphorus
and calcium in our peritoneal dialysis patients.
Methods: Forty-one clinically stable continuous ambulatory peritoneal dialysis patients using peritoneal dialysis
solution with a calcium concentration of 1.75 mmol/L participated in the study. Calcium carbonate was used
as the phosphate binder. Dietary calcium, phosphorus, and protein intake were calculated for each patient from
a 3-day dietary record; 24-hour urine, dialysate, and fasting blood were collected, and calcium, phosphorus,
and protein levels in serum, urine, and dialysate were measured.
Results: Dietary protein, phosphorus, and calcium intake were 0.79 ± 0.27 g/kg/day, 595.9 ± 174.8 mg/day,
and 441.9 ± 212.7 mg/day, respectively. Peritoneal dialysis removed 241.9 ± 87.2 mg/day phosphorus, whereas
45.4 ± 65.8 mg phosphorus was removed via urine. Hyperphosphatemia (> 1.8 mmol/L) occurred in 53.7%
of patients despite the fact that 61% of hyperphosphatemic patients received calcium carbonate. A mean of
52.6 ± 83.5 mg/day calcium was absorbed from the dialysis solution. Eight patients (19.5%) presented with
hypercalcemia. Serum phosphorus level correlated significantly with dietary protein intake (r = 0.508, p <
0.01). However, the serum calcium level did not correlate with calcium intake from diet or dialysate.
Conclusions: The incidence of hyperphosphatemia is still relatively high despite the low protein and low
phosphorus intake in our peritoneal dialysis patients. A positive calcium balance was common in our patients
using dialysis solution containing 1.75 mmol/L calcium, which needs to be further studied. [Hong Kong J
Nephrol 2004;6(2):92–6]
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Diet and phosphorus control in CAPD patients
INTRODUCTION
Adequate control of serum phosphorus is an important
aspect of the clinical management of end-stage renal
disease (ESRD) patients [1]. Hyperphosphatemia,
whether or not in conjunction with increased calcium-
phosphorus product, can cause a series of complications
such as renal osteodystrophy, secondary hyperpara-
thyroidism, and extraosseous calcification [2,3]. Cardio-
vascular calcification significantly increases patient
mortality [4].
However, successful control of hyperphosphatemia
is often limited by high dietary protein to provide
adequate nutrition in ESRD patients, poor removal of
phosphorus by dialysis, and side effects of phosphate
binders [1].
Although the recommended dietary protein intake
(DPI) for peritoneal dialysis patients is more than 1.2
g/kg/day [5], we have shown that the DPI is significantly
lower in our peritoneal dialysis patients than in their
Western counterparts [6]. The lower protein intake
should have led to easier control of hyperphosphate-
mia. However, the calcium and phosphorus balance in
Chinese peritoneal dialysis patients has not been well
studied so far.
Therefore, we investigated the phosphorus control
and the metabolic balance of phosphorus and calcium
in our peritoneal dialysis patients.
PATIENTS AND METHODS
Patients
Clinically stable continuous ambulatory peritoneal
dialysis (CAPD) patients using peritoneal dialysis
solution with a calcium concentration of 1.75 mmol/L
participated in the study. The study protocol was ap-
proved by the ethics committee of Peking University
and informed consent was obtained from each pa-
tient.
The peritoneal dialysis solution used contained a
calcium concentration of 1.75 mmol/L (Baxter Health-
care Inc, Guangzhou, China). The average daily dialysis
dose was 7,500 mL (range, 4,100–10,000 mL). Calcium
carbonate was used as the only phosphate binder and
was provided in a capsule containing 750 mg calcium
carbonate (equivalent to 300 mg of elemental calcium
per capsule).
Metabolic balance
Dietary calcium, phosphorus, and DPI were calcu-
lated for each patient from a 3-day dietary record inclu-
ding the administered calcium carbonate. All dietary
records were checked by one assigned dietitian, and
dietary calcium, phosphorus, and protein content were
calculated using a Chinese food content table.
Twenty-four-hour urine and dialysate were collected
and fasting blood was drawn on the same day. Calcium,
phosphorus, protein, blood urea nitrogen (BUN) and
creatinine (Cr) levels in the serum, urine, and dialysate
were measured using a Hitachi 7600 chemistry system
(Naka, Japan). Residual renal Kt/V and creatinine
clearance (Ccr) and peritoneal Kt/V and Ccr were cal-
culated. Normalized protein catabolic rate (nPCR)
was also calculated using the Bergstrom formula [8].
Calcium mass transfer (CMT) from the peritoneal
cavity was calculated using the formula: CMT = (A ×
B) – (C × D), where A is the calcium concentration in
fresh dialysate, B is the instilled dialysate volume, C
is the calcium concentration in effluent, and D is the
effluent volume.
Statistical analysis
Statistical analysis was performed using SPSS version
10.0 (SPSS Inc, Chicago, IL, USA) for Windows.
Results are expressed as mean ± standard deviation.
The Spearman correlation coefficient was used for
correlation analysis. A p value of less than 0.05 was
considered statistically significant.
RESULTS
Forty-one clinically stable CAPD patients (20 males
and 21 females) participated in the present study. They
represented 60% of the peritoneal dialysis population
in our institution during the study period. They were
aged 65.6 ± 9.9 years, and had been on CAPD for
23.0 ± 20.9 months (Table 1). Protein, phosphorus, and
calcium from diet and removed via dialysate and urine
are shown in Table 2.
DPI averaged 0.79 ± 0.27 g/kg/day with 32.1 ±
11.6% of the protein ingested during breakfast, 33.6 ±
9.5% during lunch, and 34.4 ± 9.6% during dinner.
Milk, eggs, and meat accounted for 43.6 ± 15.5% of
the total protein, whereas 37.1 ± 15.1% came from
cereals and legumes and the rest from fruit. There
was no significant difference between DPI and nPCR
Table 1. Demographic characteristics of the 41 patients
Male/female 20/21
Age (yr) 65.6 ± 9.9 (29–86)
Time on CAPD (mo) 23.0 ± 20.9 (3–76)
Primary disease
   Diabetic nephropathy 18
   Hypertensive nephropathy 10
   Chronic glomerulonephritis 11
   Gout nephropathy 12
   Lupus nephritis 11
   Unknown 19
CAPD = continuous ambulatory peritoneal dialysis.
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(nPCR, 0.85 ± 0.26 g/kg/day).
Dietary phosphorus intake was 595.9 ± 174.8 mg/
day. Peritoneal dialysis removed 241.9 ± 87.2 mg/day
whereas 45.4 ± 65.8 mg/day was removed via urine.
No correlation was found between serum phosphorus
level and phosphorus removed via dialysate and urine.
Weekly residual renal Kt/V and Ccr were 0.26 ± 0.39
and 9.33 ± 12.2 L, respectively. Weekly peritoneal
Kt/V and Ccr were 1.54 ± 0.43 and 41.24 ± 11.16 L,
respectively.
Hyperphosphatemia (> 1.8 mmol/L) occurred in
53.7% of patients, despite the fact that 61% of hy-
perphosphatemic patients received calcium carbon-
ate. Eighteen patients (43.9%) had elevated calcium-
phosphorus product (> 55 mg2/dL2).There was no sig-
nificant correlation between serum phosphorus level
and the dose of calcium carbonate as phosphate binder.
There were significant correlations between serum
phosphorus level and DPI (r = 0.508, p < 0.01) and
protein intake from milk, eggs, and meats (r = 0.481,
p < 0.01). However, no significant correlation was found
between serum phosphorus level and dietary protein
from other sources. The daily calcium load from diet
was 441.9 ± 212.7 mg/day. Twenty-seven patients
received calcium carbonate as phosphate binder and
their daily elemental calcium from calcium carbonate
averaged 848.2 ± 464.4 mg/day. There was significant
correlation between the dose of calcium carbonate and
DPI. The peritoneal CMT was positive and averaged
52.6 ± 83.5 mg/day. Calcium excreted via urine was
15.0 ± 27.6 mg/day. Eight patients (19.5%) presented
with hypercalcemia, three of whom received calcium
carbonate together with calcitriol. There was no sig-
nificant correlation between serum calcium level and
calcium load from diet and calcium absorption from
dialysate.
DISCUSSION
The present study showed that, despite low DPI and
phosphate intake, hyperphosphatemia in Chinese
peritoneal dialysis patients is still not uncommon.
The recommended DPI for peritoneal dialysis
patients is more than 1.2 g/kg/day, to maintain patients’
nutritional status [4]. Although it is still under debate
whether this high protein intake is reasonable, it gen-
erates more waste products that need to be removed
by dialysis [7,8]. Based on this recommendation, it is
difficult to limit the intake of dietary phosphorus to
less than 1,000 mg/day. Roughly 60–70% of consumed
phosphate will be absorbed [9]. In patients on CAPD,
the daily removal of phosphorus has been reported to
be approximately 310 mg/day, leaving about 700 mg
phosphorus to be bound per day by binders [10].
Calcium-based salts are widely used for the manage-
ment of hyperphosphatemia among dialysis patients.
Early studies found that 3–6 g of calcium carbonate
per day in ESRD patients resulted in effective control
of serum phosphorus levels [11].
The lower DPI in our patients is similar to that in
our previous report and may be a result of the Chinese
dietary culture, older age and more sedentary lifestyle
of our patients [6]. It is not surprising to find that dietary
phosphorus intake is only about half of that in reports
from Western countries. Furthermore, in our patients,
protein from high-protein sources including milk, eggs,
and meat only accounted for 44% of the total protein
intake. It is well known that dietary phosphorus ab-
sorption from the gastrointestinal system is greater
with high-quality protein than protein of plant origin,
even when the same amount of phosphorus is inges-
ted [8]. It is conceivable that, with the higher percentage
of cereal protein ingested by our patients, dietary
phosphorus absorption would be lower. Even if we
assume that 60% of dietary phosphorus has been ab-
sorbed and that phosphorus secretion by the gastro-
intestinal system is neglected, there was only a mild
positive phosphorus balance (average, 70.24 mg/day)
in our patients, and some patients even showed a nega-
tive phosphorus balance. Therefore, theoretically, on-
ly a small quantity of phosphate binder is needed to
correct the positive phosphorus balance in our patients.
However, hyperphosphatemia occurred in more than
half of our patients. The significant correlation between
serum phosphate level and DPI (as well as high-quality
protein intake) suggests that the use of phosphate
binder was inappropriate and/or inadequate. Calcium
carbonate may reduce dietary phosphorus absorption
from 60–70% to 30–40% [1,11]. Since 1,500 mg
elemental calcium can effectively control the serum
Table 2. Daily protein, calcium (Ca), and phosphorus (P) absorption and removal in the 41 patients
Protein P (mg/day) Ca (mg/day)
Intake 11 0.79 ± 0.27 g/kg/day 595.9 ± 174.8 441.9 ± 212.7
Removal
   Total 6.69 ± 2.37 g/day 287.3 ± 105.4 –37.6 ± 89.01
   Dialysate 6.15 ± 2.23 g/day 241.9 ± 87.21 –52.6 ± 83.51
   Urine 0.54 ± 0.39 g/day 145.4 ± 65.81 15.0 ± 27.6
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phosphorus level with a Western diet, the 848.2 ±
464.4 mg/day elemental calcium used in our study
should be enough to generate normophosphatemia.
Note, however, that the binding efficacy of calcium
carbonate can be affected by many factors. The timing
of phosphate binder administration in relation to meals
is important. Calcium carbonate is most effective in an
acidic environment when taken with protein-rich meals
[12]. Patient compliance is another limiting factor [9].
In fact, the serum phosphorus level has been used
as an indicator of non-compliance in dialysis patients.
In the present study, we found that only 61% of hyper-
phosphatemic patients used the phosphate binder. Even
in patients who took phosphate binder, calcium carbon-
ate was often forgotten or taken at inappropriate times.
In fact, most patients did not take phosphate binder
during breakfast, when they had a higher protein intake,
especially protein from milk and eggs. Inappropriate
use of calcium carbonate will lead not only to inade-
quate control of hyperphosphatemia, but also to
increased calcium absorption. Therefore, to improve
patients’ compliance with phosphate binder, we believe
that using approaches such as continuous quality im-
provement will decrease the incidence of hyperphos-
phatemia.
Concerns have been raised regarding the poten-
tial long-term risk of excess calcium load with cal-
cium-containing binders [1,13]. Positive CMT with
1.75 mmol/L dialysate calcium in our study was in line
with earlier reports [10,14,15]. When calcium carbonate
was taken, especially together with calcitriol, calcium
absorption increased significantly, which may have
exacerbated an already positive peritoneal CMT [16].
It is, thus, not surprising that eight of our patients
presented with hypercalcemia. On the other hand, an
excess calcium load may not necessarily be reflected
in elevated serum calcium levels. Serum calcium level
is a poor indicator of total body calcium load because
the overwhelming majority (99%) of total body calcium
is sequestered in the bone, and only about 0.025% is
found in the plasma. Although the long-term effect of
a positive calcium balance in our patients is still unclear,
the high cardiovascular mortality in peritoneal dialysis
patients warrants further study of the use of lower-
calcium peritoneal dialysis solutions (1.5 mmol/L or
even 1.25 mmol/L calcium).
The role of residual renal function in removing
phosphorus and calcium has, to a large extent, been
neglected. Our study found that residual renal function
contributed significantly to the removal of phosphorus
and calcium, especially calcium, and facilitated the
maintenance of phosphorus and calcium balance.
In conclusion, the low-protein and low-phosphorus
diet in Chinese peritoneal dialysis patients should have
made it easier to control serum phosphorus and to
use less calcium carbonate. However, the incidence of
hyperphosphatemia was still relatively high. Further
approaches such as applying continuous quality
improvement to ensure patient compliance and the
appropriate use of phosphate binder may decrease
the incidence of hyperphosphatemia. On the other
hand, a positive calcium balance was seen in most
of our patients using dialysis solution containing
1.75 mmol/L calcium. The long-term effect of this
positive calcium balance remains to be elucidated.
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